Editor's Summary
29 November 2007
SIRT1 activators in diabetes
SIRT1, an NAD+-dependent deacetylase that acts on proteins involved in cellular regulation, has been implicated in longevity and as a mediator of the beneficial effects of calorie restriction. A new screening programme has identified a series of small-molecule SIRT1 activators that are structurally unlike, and 1,000-fold more potent than, resveratrol, the well-known SIRT1 activator found in red wine. These new compounds improve metabolic function in animal models of diabetes and obesity, suggesting that they may have therapeutic potential in type 2 diabetes and insulin resistance.
Letter: Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Jill C. Milne, Philip D. Lambert, Simon Schenk, David P. Carney, Jesse J. Smith, David J. Gagne, Lei Jin, Olivier Boss, Robert B. Perni, Chi B. Vu, Jean E. Bemis, Roger Xie, Jeremy S. Disch, Pui Yee Ng, Joseph J. Nunes, Amy V. Lynch, Hongying Yang, Heidi Galonek, Kristine Israelian, Wendy Choy, Andre Iffland, Siva Lavu, Oliver Medvedik, David A. Sinclair, Jerrold M. Olefsky, Michael R. Jirousek, Peter J. Elliott & Christoph H. Westphal
doi:10.1038/nature06261
First paragraph | Full Text | PDF (327K) | Supplementary information
